Atomo's Blood Test Unveiled at 2014 AACC; Takes Top Award in NY
|
By LabMedica International staff writers Posted on 01 Aug 2014 |
|
Atomo Diagnostics (Melbourne, Australia) showcased integrated rapid blood test device to the USA market at the 2014 AACC Annual Meeting and Clinical Lab Expo, following a successful presentation at the 20th International AIDS Conference 2014 in Melbourne (Australia). The AtomoRapid all-in-one blood test can accommodate test strips for a wide variety of conditions from celiac disease and allergy through to infectious diseases such as malaria and human immunodeficiency virus (HIV).
The device delivers better clinical outcomes for patients and health care providers by enabling simpler, safer, and more accurate testing in the field or at home.
At AIDS 2014, Atomo Diagnostics participated in a conference session organized by the World Health Organization (WHO; Basel, Switzerland). The session focused on opportunities and challenges facing self-testing and a debate about real world situations. The AtomoRapid all-in-one blood test, which is half the size of an iPhone, has been deployed in South Africa for HIV and malaria testing, and clinical activities are in process in the EU and in planning in Asia and the USA.
Former ResMed executive and Atomo Diagnostics’ founder and CEO John Kelly MSc, BEng, comments: ”We have started with HIV and malaria because that was where false negatives and false positives from other existing ‘bits in a box’ products, which were sometimes greater than 10% when used in the field, were having the most significant impact on individuals.”
AtomoRapid HIV could play a significant role in supporting the Australian Government’s initiative to lift restrictions on home HIV testing. Around 30% of Australians with HIV are diagnosed well after they should have started treatment to restore their damaged immune system, according to the latest Annual HIV Surveillance report from the UNSW’s Kirby Institute (Sydney, Australia) Annual Symposium.
John Kelly adds, "We have seen from our work with the Desmond Tutu HIV Foundation in South Africa that if you want to be accepted as an at-home test you need an integrated intuitive solution that reduces test errors." Kelly was inspired to find a better way to test blood when his daughter developed a childhood disease requiring regular blood draws for diagnostic tests.
Given its ease of use and simplicity, AtomoRapid has the ability to materially improve both the uptake and reliability of testing in the community and at home. The company is currently implementing its plans to launch the product in Australia, the US, and Europe for both professional and at home use.
Over 100 million rapid HIV tests are bought each year globally, and Atomo Diagnostics is leading the transition to more user friendly all-in-one solution with its AtomoRapid innovation.
AtomoRapid took the top international medical technology award last month in New York at the Medical Design Excellence Awards and has been given a number of other important honors.
Related Links:
Atomo Diagnostics
World Health Organization
Kirby Institute
The device delivers better clinical outcomes for patients and health care providers by enabling simpler, safer, and more accurate testing in the field or at home.
At AIDS 2014, Atomo Diagnostics participated in a conference session organized by the World Health Organization (WHO; Basel, Switzerland). The session focused on opportunities and challenges facing self-testing and a debate about real world situations. The AtomoRapid all-in-one blood test, which is half the size of an iPhone, has been deployed in South Africa for HIV and malaria testing, and clinical activities are in process in the EU and in planning in Asia and the USA.
Former ResMed executive and Atomo Diagnostics’ founder and CEO John Kelly MSc, BEng, comments: ”We have started with HIV and malaria because that was where false negatives and false positives from other existing ‘bits in a box’ products, which were sometimes greater than 10% when used in the field, were having the most significant impact on individuals.”
AtomoRapid HIV could play a significant role in supporting the Australian Government’s initiative to lift restrictions on home HIV testing. Around 30% of Australians with HIV are diagnosed well after they should have started treatment to restore their damaged immune system, according to the latest Annual HIV Surveillance report from the UNSW’s Kirby Institute (Sydney, Australia) Annual Symposium.
John Kelly adds, "We have seen from our work with the Desmond Tutu HIV Foundation in South Africa that if you want to be accepted as an at-home test you need an integrated intuitive solution that reduces test errors." Kelly was inspired to find a better way to test blood when his daughter developed a childhood disease requiring regular blood draws for diagnostic tests.
Given its ease of use and simplicity, AtomoRapid has the ability to materially improve both the uptake and reliability of testing in the community and at home. The company is currently implementing its plans to launch the product in Australia, the US, and Europe for both professional and at home use.
Over 100 million rapid HIV tests are bought each year globally, and Atomo Diagnostics is leading the transition to more user friendly all-in-one solution with its AtomoRapid innovation.
AtomoRapid took the top international medical technology award last month in New York at the Medical Design Excellence Awards and has been given a number of other important honors.
Related Links:
Atomo Diagnostics
World Health Organization
Kirby Institute
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Latest AACC 2014 News
- Corgenix Diagnostic Ebola Test Research Earns Abstract Award
- Roche Partners with Customers, Redefines Laboratory Value
- Abbott Showcases Innovations, Helps Labs Solve Health Care Challenges
- Sony DADC BioSciences and TSMC Receive AACC Award
- Oncolab Exhibits Pioneering AMAS Cancer Test at AACC
- Thermo Fisher Scientific Showcases Expanded Offering for Clinical Laboratory
- Major Advances in Medical Studies Highlighted at AACC 2014
- Wheaton Offers Unique Solutions for the Clinical Market
- Seegene Reveals New Real-Time PCR at AACC 2014
- AACC Debuts Refreshed Brand Identity
- Mobile Health, Big Data, Antimicrobial Resistance Central to 2014 Meeting
- EKF Highlights Growing Product Portfolio at AACC 2014 Meeting
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read more
Molecular Diagnostics
view channel
Simple Urine Test to Revolutionize Bladder Cancer Diagnosis and Treatment
Bladder cancer is one of the most common and deadly urological cancers and is marked by a high rate of recurrence. Diagnosis and follow-up still rely heavily on invasive cystoscopy or urine cytology, which... Read more
Blood Test to Enable Earlier and Simpler Detection of Liver Fibrosis
Persistent liver damage caused by alcohol misuse or viral infections can trigger liver fibrosis, a condition in which healthy tissue is gradually replaced by collagen fibers. Even after successful treatment... Read more
Hematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Immunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read more
Microbiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read more
Rapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read more
Pathology
view channel
Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
Isolating rare cancer cells from blood is essential for diagnosing metastasis and guiding treatment decisions, but remains technically challenging. Many existing techniques struggle to balance accuracy,... Read more
AI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read more
Technology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
Industry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more
